Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Acarbose
5%
All Cause Mortality
8%
Antidiabetic Agent
9%
Atosiban
8%
Breast Cancer
9%
Cardiovascular Disease
47%
Cerebrovascular Accident
5%
Chemotherapy
11%
Chronic Kidney Failure
11%
Cohort Study
49%
Comorbidity
17%
Congestive Heart Failure
15%
Cyclorphan
8%
Diabetic Retinopathy
5%
Dipeptidyl Peptidase IV Inhibitor
33%
Diseases
10%
Effectiveness Study
6%
End Stage Renal Disease
8%
Endometriosis
8%
Glucagon Like Peptide 1 Receptor Agonist
33%
Heart Infarction
5%
HIV
13%
Human Insulin
8%
Hypoglycemia
26%
Insulin Analog
12%
Insulin Dependent Diabetes Mellitus
12%
Liver Cell Carcinoma
8%
Long Acting Insulin
24%
Maturity Onset Diabetes of the Young
8%
Metabolic Syndrome X
8%
Metformin
9%
Microangiopathy
6%
Non Insulin Dependent Diabetes Mellitus
100%
Oral Antidiabetic Agent
8%
Prevalence
6%
Recombinant Human Insulin
8%
Retinopathy
10%
Sodium Glucose Cotransporter 2 Inhibitor
8%
sodium glucose cotransporter-2 inhibitors
24%
Sulfonylurea
18%
Survival Time
5%
Triple Negative Breast Cancer
8%
Medicine and Dentistry
Adenomyosis
8%
Apoplexy
12%
Breast Cancer
9%
Cardiovascular Disease
16%
Cardiovascular Risk
5%
Cardiovascular System
17%
Cohort Analysis
18%
Comorbidity
10%
Congestive Heart Failure
13%
Cost-Effectiveness Analysis
25%
Diabetes
15%
Dipeptidyl Peptidase-4 Inhibitor
14%
Electronic Health Record
10%
Endometriosis
12%
Fertilization
5%
Glomerular Filtration Rate
8%
Glucagon-Like Peptide-1 Agonist
12%
Glycemic Control
5%
Glycon
8%
Hazard Ratio
12%
Health Care
8%
Health Care Cost
24%
Hemoglobin A1c
5%
Human immunodeficiency virus
8%
Human Insulin
12%
Hypoglycemia
6%
Insulin Dependent Diabetes Mellitus
8%
Lifespan
6%
Long Acting Insulin
16%
Maturity Onset Diabetes of the Young
37%
Microangiopathy
6%
Myocardial Infarction
5%
Oral Antidiabetic Agent
5%
Patient with Type 1 Diabetes
5%
Patient with Type 2 Diabetes
26%
Polycystic Ovary Syndrome
12%
Prevalence
5%
Proportional Hazards Model
7%
Quality Adjusted Life Year
7%
Quality of Life
24%
Recombinant Human Insulin
12%
Retinopathy
5%
Sodium Glucose Cotransporter 2 Inhibitor
15%
Survival Time
5%
Treatment Effect
9%
Triple Negative Breast Cancer
8%
Keyphrases
A1 Receptor
6%
Cardiovascular Disease
5%
Clinical Outcomes
5%
Dipeptidyl peptidase-4 (DPP-4)
12%
Economic Burden
5%
Embryo Transfer Cycle
5%
GLP-1 Receptor Agonist
8%
Glucagon-like
6%
Glucagon-like peptide-1 Receptor (GLP-1R)
7%
Incidence Rate
5%
Long-acting Insulin
8%
Population-based Cohort Study
8%
Receptor Agonist
6%
Recurrent Event Data
8%
Recurrent Events
8%
Risk Equations
8%
Taiwan
17%
Type 2 Diabetes Mellitus (T2DM)
12%
Type 2 Diabetic Patients
19%
